ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on

ADC Therapeutics to Host Fourth Quarter and Year-End

Financial Results Conference Call on March 3,

Lausanne, Switzerland,

February 24, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those

affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and

solid tumors, today announced that it will host a conference call and live webcast on Thursday, March 3, 2022 at 8:30 a.m. ET to report

financial results for the fourth quarter and year-end 2021 and provide business updates.

call, please dial 833-303-1198 (domestic) or +1 914-987-7415 (international) and provide conference

ID 8189237. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section

of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

(NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted

antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm

for patients with hematologic malignancies and solid tumors.

CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse

large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents.

Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase

1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing

clinical and preclinical development.

is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information,

please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA is a registered trademark

of ADC Therapeutics SA.

Tel.: +44 7879 627205

Tel.: +1 917 288 7023

Tel: +41 (0) 43 268 3231

Tel.: +1 914-552-4625